Pharmaceutical industry – Page 26
-
ResearchCatalyst puts chiral twist on phosphorus drugs
Simple molecule overcomes headache of phosphorus stereochemistry in antiviral drug synthesis
-
BusinessFresenius to buy Akorn and Merck KGaA’s biosimilars
Deals give Fresenius entry into rapidly growing biological drugs market
-
OpinionAlternate chemical realities
What would chemistry look like if key discoveries had happened differently?
-
BusinessHow do chemical firms last hundreds of years?
What distinguishes companies that thrive from others that failed?
-
BusinessJob cuts at Amgen, Takeda and Vertex
Takeda reorganising following Ariad takeover, while Amgen and Vertex move staff to Cambridge and San Francisco hubs
-
FeatureThe flow revolution
Continuous approaches are starting to find use in fine chemicals, as Angeli Mehta discovers
-
BusinessLilly loses arbitration over Canadian patents
Firm had sought recompense under the Nafta trade agreement
-
BusinessEU recommends withdrawing drugs approved on unreliable data
Indian firm Micro Therapeutic Research Labs accused of misrepresenting clinical data and documentation deficiencies
-
BusinessIndian drug industry opposes price caps
Government wants free healthcare for poorest people, but companies claim controls will stifle innovation
-
BusinessExpanding precision medicine beyond cancer
Exclusive interview with Koustubh Ranade, vice president of R&D at MedImmune
-
OpinionHow does being a chemist change your view on the world?
Scientific knowledge and analysis shape our view, but can also be selectively ignored
-
WhitepaperAnalytical method transfer
Learn about current best practice in a critical field for the industry
-
BusinessJ&J to close Scottish medical device plant
Up to 400 positions affected as Ethicon subsidiary leaves Livingston
-
FeatureHow ketamine could help treat severe depression
Nina Notman looks at how the party drug ketamine may hold the key to treating patients with severe depression
-
OpinionOutlines of ignorance
There’s a lot about chemistry that we just don’t understand very well yet
-
OpinionCollaboration and competition can both stimulate innovation
Diverse approaches suit different goals
-
BusinessCrispr patent ruling breaks deadlock
Both sides claim victory as board rules patents do not interfere with each other
-
Business$2bn Immunomedics–Seattle Genetics deal delayed amid shareholder infighting
Major investor venBio seeks to derail deal and replace board members
-
FeatureDeal or no deal?
Clare Sansom highlights recent changes in the landscape of pharma company collaborations and acquisitions
-
BusinessUniversity–industry collaborations aspire to pharmaceutical innovation
Three new UK partnerships illustrate drug research co-operation approaches that are growing in popularity